Published in Radiol Phys Technol on February 03, 2015
Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer (2004) 4.54
Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys (2005) 4.14
Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol (2007) 3.91
Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys (2010) 3.66
Thyroid gland tumor diagnosis at US elastography. Radiology (2005) 3.26
Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol (2009) 3.12
Cervical lymph node metastases: diagnosis at sonoelastography--initial experience. Radiology (2007) 2.56
Regional hyperthermia combined with radiotherapy for uterine cervical cancers: a multi-institutional prospective randomized trial of the international atomic energy agency. Int J Radiat Oncol Biol Phys (2005) 2.19
Stereotactic body radiotherapy for oligometastatic lung tumors. Int J Radiat Oncol Biol Phys (2008) 2.11
Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol (2012) 2.03
A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study (JCOG9708). Jpn J Clin Oncol (2009) 1.99
Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. J Clin Invest (2005) 1.94
Inhibitory and stimulatory regulation of Rac and cell motility by the G12/13-Rho and Gi pathways integrated downstream of a single G protein-coupled sphingosine-1-phosphate receptor isoform. Mol Cell Biol (2003) 1.94
Vertebrate POLQ and POLbeta cooperate in base excision repair of oxidative DNA damage. Mol Cell (2006) 1.79
Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res (2007) 1.77
Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys (2010) 1.71
Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: Based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011. Breast Cancer (2015) 1.64
Patterns of practice in palliative radiotherapy for painful bone metastases: a survey in Japan. Int J Radiat Oncol Biol Phys (2012) 1.60
Sphingosine-1-phosphate, a platelet-derived lysophospholipid mediator, negatively regulates cellular Rac activity and cell migration in vascular smooth muscle cells. Circ Res (2002) 1.59
Treatment of acquired perforating dermatosis with narrowband ultraviolet B. J Am Acad Dermatol (2004) 1.59
Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res (2004) 1.58
Characteristics of patients who developed radiation pneumonitis requiring steroid therapy after stereotactic irradiation for lung tumors. Cancer J (2006) 1.52
Tumor hypoxia: a target for selective cancer therapy. Cancer Sci (2003) 1.49
Clinical outcomes of 3D conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic body frame. Int J Radiat Oncol Biol Phys (2002) 1.48
Survey of stereotactic body radiation therapy in Japan by the Japan 3-D Conformal External Beam Radiotherapy Group. Int J Radiat Oncol Biol Phys (2009) 1.47
Delayed initial radioactive iodine therapy resulted in poor survival in patients with metastatic differentiated thyroid carcinoma: a retrospective statistical analysis of 198 cases. J Nucl Med (2011) 1.45
Treatment of chronic actinic dermatitis with tacrolimus ointment. J Am Acad Dermatol (2002) 1.45
Dose--volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys (2012) 1.43
Epidermoid cyst: rare testicular tumor in children. Pediatr Radiol (2003) 1.42
Effects of antioxidants and NO on TNF-alpha-induced adhesion molecule expression in human pulmonary microvascular endothelial cells. Respir Med (2004) 1.41
Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma. J Clin Oncol (2005) 1.40
Stereotactic body radiotherapy using a radiobiology-based regimen for stage I nonsmall cell lung cancer: a multicenter study. Cancer (2011) 1.40
A consensus-based guideline defining the clinical target volume for pelvic lymph nodes in external beam radiotherapy for uterine cervical cancer. Jpn J Clin Oncol (2010) 1.39
The Akt/mTOR pathway assures the synthesis of HIF-1alpha protein in a glucose- and reoxygenation-dependent manner in irradiated tumors. J Biol Chem (2008) 1.38
Optical imaging of tumor hypoxia and evaluation of efficacy of a hypoxia-targeting drug in living animals. Mol Imaging (2005) 1.35
Primary bone lymphoma: a new and detailed characterization of 28 patients in a single-institution study. Jpn J Clin Oncol (2007) 1.31
Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels. Nat Commun (2012) 1.30
Development of a four-dimensional image-guided radiotherapy system with a gimbaled X-ray head. Int J Radiat Oncol Biol Phys (2006) 1.29
Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer. Jpn J Clin Oncol (2005) 1.29
Elective nodal irradiation (ENI) in definitive chemoradiotherapy (CRT) for squamous cell carcinoma of the thoracic esophagus. Radiother Oncol (2008) 1.28
High-dose proton beam therapy for Stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2006) 1.28
Prognostic factors in stereotactic body radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2010) 1.27
Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells. Cancer Res (2002) 1.27
Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3)N(any) M(0) squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys (2003) 1.25
The combination of hypoxia-response enhancers and an oxygen-dependent proteolytic motif enables real-time imaging of absolute HIF-1 activity in tumor xenografts. Biochem Biophys Res Commun (2007) 1.22
Evaluation of lung injury after three-dimensional conformal stereotactic radiation therapy for solitary lung tumors: CT appearance. Radiology (2003) 1.20
EMR as salvage treatment for patients with locoregional failure of definitive chemoradiotherapy for esophageal cancer. Gastrointest Endosc (2003) 1.19
Association of over-expressed TFDP1 with progression of hepatocellular carcinomas. J Hum Genet (2003) 1.17
Interinstitutional variations in planning for stereotactic body radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys (2007) 1.14
Cholangitis and liver abscess after percutaneous ablation therapy for liver tumors: incidence and risk factors. J Vasc Interv Radiol (2003) 1.14
Selective killing of hypoxia-inducible factor-1-active cells improves survival in a mouse model of invasive and metastatic pancreatic cancer. Clin Cancer Res (2009) 1.13
Characterization of FDG-PET images after stereotactic body radiation therapy for lung cancer. Radiother Oncol (2010) 1.12
Evaluation of mass-like consolidation after stereotactic body radiation therapy for lung tumors. Int J Clin Oncol (2007) 1.11
Early protective effect of bone marrow mononuclear cells against ischemic white matter damage through augmentation of cerebral blood flow. Stroke (2010) 1.11
Multi-institutional analysis of solitary extramedullary plasmacytoma of the head and neck treated with curative radiotherapy. Int J Radiat Oncol Biol Phys (2011) 1.11
Evaluation of primary brain tumors with FLT-PET: usefulness and limitations. Clin Nucl Med (2006) 1.10
Primary mediastinal large B-cell lymphoma: a single-institution clinical study in Japan. Int J Hematol (2004) 1.10
Postoperative radiotherapy for intracranial ependymoma: analysis of prognostic factors and patterns of failure. J Neurooncol (2002) 1.10
Dosimetric verification in participating institutions in a stereotactic body radiotherapy trial for stage I non-small cell lung cancer: Japan clinical oncology group trial (JCOG0403). Phys Med Biol (2006) 1.10
General rules for clinical and pathological recording of breast cancer 2005. Breast Cancer (2005) 1.08
Palliative radiation therapy for hemorrhage of unresectable gastric cancer: a single institute experience. J Cancer Res Clin Oncol (2009) 1.08
Prospective multi-institutional study of definitive radiotherapy with high-dose-rate intracavitary brachytherapy in patients with nonbulky (<4-cm) stage I and II uterine cervical cancer (JAROG0401/JROSG04-2). Int J Radiat Oncol Biol Phys (2011) 1.07
Outcome of pediatric renal tumor treated using the Japan Wilms Tumor Study-1 (JWiTS-1) protocol: a report from the JWiTS group. Pediatr Surg Int (2009) 1.06
Microenvironment and radiation therapy. Biomed Res Int (2012) 1.06
Heme oxygenase-1 production by peripheral blood monocytes during acute inflammatory illnesses of children. Exp Biol Med (Maywood) (2003) 1.06
Proton beam therapy for unresectable malignancies of the nasal cavity and paranasal sinuses. Int J Radiat Oncol Biol Phys (2010) 1.05
Long-term outcome after surgical treatment of arterial lesions in Behçet disease. J Vasc Surg (2005) 1.05
M(2) and M(3) muscarinic receptor-mediated contractions in longitudinal smooth muscle of the ileum studied with receptor knockout mice. Br J Pharmacol (2005) 1.05
Suppression of VEGF transcription in renal cell carcinoma cells by pyrrole-imidazole hairpin polyamides targeting the hypoxia responsive element. Acta Oncol (2006) 1.04
TS-1 enhances the effect of radiotherapy by suppressing radiation-induced hypoxia-inducible factor-1 activation and inducing endothelial cell apoptosis. Cancer Sci (2008) 1.04
The HIF-1-active microenvironment: an environmental target for cancer therapy. Adv Drug Deliv Rev (2009) 1.03
Outcome of percutaneous transhepatic venoplasty for hepatic venous outflow obstruction after living donor liver transplantation. Radiology (2006) 1.03
Local hyperthermia combined with external irradiation for regional recurrent breast carcinoma. Int J Clin Oncol (2004) 1.02
A second generation genetic linkage map of Japanese flounder (Paralichthys olivaceus). BMC Genomics (2010) 1.02
Sarcoidosis and molecular mimicry--important etiopathogenetic aspects: current state and future directions. Wien Klin Wochenschr (2012) 1.01
Japanese multicenter phase II study of CHOP followed by radiotherapy in stage I-II, diffuse large B-cell lymphoma of the stomach. Cancer Sci (2005) 1.01
18F-FDG and 11C-methionine PET for evaluation of treatment response of lung cancer after stereotactic radiotherapy. Ann Nucl Med (2004) 1.01
Early sensitization to house dust mite is a major risk factor for subsequent development of bronchial asthma in Japanese infants with atopic dermatitis: results of a 4-year followup study. Ann Allergy Asthma Immunol (2002) 1.00
Treatment planning of stereotactic radiotherapy for solitary lung tumor. Int J Radiat Oncol Biol Phys (2005) 1.00
Measurement of neutron ambient dose equivalent in passive carbon-ion and proton radiotherapies. Med Phys (2008) 1.00
Transthoracic percutaneous radiofrequency ablation for liver tumors in the hepatic dome. J Vasc Interv Radiol (2004) 1.00
IL12RB2 and ABCA1 genes are associated with susceptibility to radiation dermatitis. Clin Cancer Res (2008) 0.99
Development of an easy-to-handle range measurement tool using a plastic scintillator for proton beam therapy. Phys Med Biol (2006) 0.99
Proton-beam therapy for olfactory neuroblastoma. Int J Radiat Oncol Biol Phys (2007) 0.98
Near-infrared fluorescence tumor imaging using nanocarrier composed of poly(L-lactic acid)-block-poly(sarcosine) amphiphilic polydepsipeptide. Biomaterials (2009) 0.98
Near-infrared fluorescent labeled peptosome for application to cancer imaging. Bioconjug Chem (2007) 0.98
Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). Cancer Sci (2015) 0.98
Proton beam therapy as a nonsurgical approach to mucosal melanoma of the head and neck: a pilot study. Int J Radiat Oncol Biol Phys (2010) 0.98
Comparison of the antioxidant activity of roasted tea with green, oolong, and black teas. Int J Food Sci Nutr (2005) 0.97
In vivo imaging of HIF-active tumors by an oxygen-dependent degradation protein probe with an interchangeable labeling system. PLoS One (2010) 0.97
A novel screen using the Reck tumor suppressor gene promoter detects both conventional and metastasis-suppressing anticancer drugs. Oncotarget (2010) 0.97
Microdosimetric measurements and estimation of human cell survival for heavy-ion beams. Radiat Res (2006) 0.97
Standard thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer: a phase III trial of the Japan Clinical Oncology Group (JCOG9812). Jpn J Clin Oncol (2005) 0.97